Posted by Michael Wonder on 18 Oct 2016
NICE publishes evaluation consultation document for for migalastat hydrochloride
18 October 2016 - NICE has published draft guidance on this highly specialised technology.
The case for national commissioning of migalastat is supported when used within its marketing authorisation, as an option for treating Fabry disease in people over 16 with amenable mutations. With the discount agreed in the patient access scheme, migalastat provides health benefits at a lower cost than enzyme replacement therapy at its current price.
